Russell Investments Group Ltd. Cuts Stake in Insmed, Inc. $INSM

Russell Investments Group Ltd. reduced its position in Insmed, Inc. (NASDAQ:INSM) by 22.6% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 234,617 shares of the biopharmaceutical company’s stock after selling 68,379 shares during the period. Russell Investments Group Ltd.’s holdings in Insmed were worth $23,612,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in INSM. ORG Partners LLC increased its position in Insmed by 220.2% during the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 196 shares during the period. Hilltop National Bank bought a new position in shares of Insmed during the second quarter valued at approximately $28,000. FNY Investment Advisers LLC purchased a new position in Insmed during the second quarter valued at approximately $33,000. LRI Investments LLC bought a new position in Insmed in the second quarter worth approximately $59,000. Finally, Strategic Investment Solutions Inc. IL bought a new position in Insmed in the first quarter worth approximately $79,000.

Insmed Price Performance

Shares of NASDAQ INSM opened at $206.43 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. The company has a market cap of $44.02 billion, a PE ratio of -36.15 and a beta of 1.05. The business has a 50-day simple moving average of $173.90 and a two-hundred day simple moving average of $130.08. Insmed, Inc. has a fifty-two week low of $60.40 and a fifty-two week high of $209.77.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The company had revenue of $142.34 million for the quarter, compared to analyst estimates of $114.33 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business’s revenue was up 52.4% compared to the same quarter last year. During the same quarter last year, the company earned ($1.27) EPS. Insmed has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. UBS Group increased their target price on Insmed from $194.00 to $223.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Morgan Stanley raised their price objective on Insmed from $126.00 to $144.00 and gave the company an “equal weight” rating in a research report on Thursday, August 21st. Wells Fargo & Company lifted their target price on Insmed from $171.00 to $217.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. JPMorgan Chase & Co. raised their price target on shares of Insmed from $111.00 to $135.00 and gave the company an “overweight” rating in a report on Wednesday, August 20th. Finally, Stifel Nicolaus lifted their price objective on shares of Insmed from $121.00 to $145.00 and gave the stock a “buy” rating in a research report on Thursday, August 14th. Nineteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $175.53.

Insider Buying and Selling at Insmed

In other Insmed news, Director Leo Lee sold 75,000 shares of the firm’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $195.90, for a total value of $14,692,500.00. Following the completion of the transaction, the director owned 54,677 shares of the company’s stock, valued at approximately $10,711,224.30. This trade represents a 57.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Elizabeth M. Anderson sold 10,000 shares of Insmed stock in a transaction on Friday, November 14th. The stock was sold at an average price of $195.87, for a total transaction of $1,958,700.00. Following the sale, the director owned 63,729 shares of the company’s stock, valued at $12,482,599.23. The trade was a 13.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 257,922 shares of company stock worth $44,556,283 in the last three months. 3.00% of the stock is owned by company insiders.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.